Skip to main content
Full access
Communications and Updates
Published Online: 1 March 2011

Oxybutynin for Antidepressant-Induced Hyperhidrosis

To the Editor: Hyperhidrosis, or excessive sweating, can be an uncomfortable and embarrassing side effect of antidepressants. It is estimated to occur in 14% of patients taking tricyclic antidepressants (1). The presumed mechanism of tricyclic antidepressant-induced sweating is the inhibited reuptake of norepinephrine, leading to the stimulation of peripheral adrenergic receptors (2).
Sweat glands are innervated by peripheral sympathetic nerves, which are mediated by acetylcholine. Oxybutynin, an anticholinergic drug that is registered for urge incontinence, has shown to be effective in the treatment of excessive sweating in some cases (3) but has not yet been reported to be effective in cases of antidepressant-induced sweating. Here, I present two cases in which oxybutynin was successfully introduced to decrease excessive sweating.
Patient A is a 59-year-old man with a history of recurrent episodes of panic disorder, for which he had used paroxetine, venlafaxine, and escitalopram as well as high doses of oxazepam in the past. He was admitted to the hospital because of a severe depressive episode with suicidal ideation. The depression was successfully treated with clomipramine, 100 mg/day, which was effective for the treatment of panic attacks as well. Although he sweated all over his body, he was willing to continue clomipramine monotherapy after discharge. Lowering the dosage did not change the situation, nor did treatment with cognitive-behavioral therapy. Finally, a trial with oxybutynin, 2.5 mg b.i.d., relieved the hyperhidrosis completely, without any side effects.
Patient B is a 60-year-old man with recurrent severe depressive episodes with psychotic symptoms and agitation. Typical for his disorder are the rapid onset of relapse and the severity of agitation, which in the past required hospitalization and seclusion. In the latest episode he was treated with clomipramine, 75 mg/day, and olanzapine, 15 mg/day, but he suffered from severe hyperhidrosis. A switch from olanzapine to haloperidol did not change the hyperhidrosis. Later, 800 mg/day of lithium was successfully added for the treatment of his depressive symptoms. Oxybutynin, 5 mg t.i.d., was added to his treatment and relieved his hyperhidrosis without side effects.
There are several preferential strategies to treat hyperhidrosis, such as lowering the dosage or altering the dosing schedule, changing clothing or food habits, or regulating anxiety (2). In the present two cases, these strategies were unsuccessful and oxybutynin maintenance treatment was introduced. With its rapid, short-term effect (within an hour), oxybutynin could also be considered “as needed” in specific social situations. One should be careful in dosing to avoid anticholinergic side effects such as constipation, urinary retention, and blurred vision. Although placebo-controlled research is necessary, the cases reported here suggest that adding oxybutynin to antidepressants can be a simple and effective treatment option for hyperhidrosis.

Footnote

This letter was accepted for publication in December 2010.

References

1.
Marcy TR, Britton ML: Antidepressant-induced sweating. Ann Pharmacother 2005; 39:748–752
2.
Cheshire WP, Fealey RD: Drug-induced hyperhidrosis and hypohidrosis: incidence, prevention, and management. Drug Saf 2008; 31:109–126
3.
Mijnhout GS, Kloosterman H, Simsek S, Strack van Schijndel RJM, Netelenbos JC: Oxybutynin: dry days for patients with hyperhidrosis. Neth J Med 2006; 64:326–328

Information & Authors

Information

Published In

Go to American Journal of Psychiatry
Go to American Journal of Psychiatry
American Journal of Psychiatry
Pages: 330 - 331
PubMed: 21368313

History

Accepted: December 2010
Published online: 1 March 2011
Published in print: March 2011

Authors

Details

Koen P. Grootens, M.D., Ph.D.
Nijmegen, the Netherlands

Funding Information

Dr. Grootens reports no financial relationships with commercial interests.

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

View Options

View options

PDF/EPUB

View PDF/EPUB

Get Access

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login
Purchase Options

Purchase this article to access the full text.

PPV Articles - American Journal of Psychiatry

PPV Articles - American Journal of Psychiatry

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share